News and Announcements
OpenDNA’s Patented Technology Reinforces the Company’s Unique Selling Proposition
- Published August 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OpenDNA Limited (ASX:OPN) is pleased to provide the company’s quarterly activities report and Appendix 4C for the quarter ended 30 June 2017.
KEY TAKEAWAYS:
- Key technological advances made to bolster and leverage the Company’s core artificial intelligence system.
- Updated and additions to OpenDNA’s patented technology reinforces the company’s unique selling proposition.
- Key new market sectors, including mobile phone handsets, food & beverage, luxury goods.
- Development and conversion of potential customer pipeline, with signature of additional customer agreements expected imminently.
OpenDNA’s Chief Executive Officer and MD, Jay Shah, commented on progress during the Quarter by saying:
“OpenDNA is focused on providing the most useful, relevant insights to customers regardless of the industry they operate in and we are working continually to develop ways in which to reinforce the Company’s USP for those customers. By understanding how to make our personalization and psychographic insights most useful to customers, and developing new technologies which enhance that usefulness, we are simultaneously improving our offering to current and potential customers alike. In this Quarter we have begun to see the results of the consistent efforts being made by our sales force to secure agreements with customers operating in a range of industries and we look forward to that trend continuing and increasing during the September Quarter”.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
